HPEL (Hyperlipidemia) Predicted ASCVD Increment Calculator
- Current LDL-C (mg/dL)
- Reference/Target LDL-C (mg/dL) (e.g., 70)
- HPEL (Hyperlipidemia) Predicted ASCVD Increment: Explanation and Clinical Context
This tool estimates the incremental atherosclerotic cardiovascular disease (ASCVD) risk attributable to elevated LDL-C relative to a user-defined reference (commonly 70 mg/dL) by applying a log-linear relationship between LDL-C and major vascular events derived from large, individual-patient meta-analyses.
Users first enter a baseline 10-year ASCVD risk (e.g., from the ACC/AHA Pooled Cohort Equations) and then input the current and reference LDL-C. The calculator applies a multiplicative risk multiplier based on the well-established finding that each 1.0 mmol/L (≈38.7 mg/dL) reduction in LDL-C is associated with about a 21–22% relative reduction in major vascular events (rate ratio ≈0.79). Accordingly, an LDL-C elevation above the reference produces a proportional increase in predicted risk. The output includes the adjusted 10-year risk, the absolute (%-point) increase, and the relative (%) increase versus baseline.
Clinical Significance
The approach reflects the causal, continuous, and log-linear exposure–response between LDL-C and ASCVD. It complements (not replaces) global risk estimators by making the LDL-attributable component explicit, useful for shared decision-making about lipid-lowering therapy intensity and targets. Because the underlying evidence shows consistent proportional benefit across risk strata, the same multiplier can be applied to a wide range of baseline risks. However, estimates are approximations: they assume average treatment effects and do not account for competing risks, polygenic risk, or additional lipoproteins (e.g., Lp(a), ApoB, sdLDL), which can further modify risk.
Clinical Interpretation Summary
• If current LDL-C is higher than the reference, the predicted risk increases multiplicatively; if lower, it decreases.
• The absolute risk difference is often more actionable for therapy decisions than the relative increment alone.
• Always interpret in the context of the patient’s overall risk profile, preferences, therapy tolerability, and guideline recommendations.
Reference:
Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy. Lancet. 2012;380:581-590. Rate ratio ≈0.79 per 1.0 mmol/L LDL-C reduction.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol. Lancet. 2010;376:1670-1681. Consistent proportional risk reduction per mmol/L across populations.
ACC/AHA ASCVD Risk Estimator Plus. Baseline 10-year risk estimation for primary prevention. Use as the baseline risk input for this tool.
Discussion
No discussions yet. Be the first to comment.
Create Note
Notes are stored privately on your device only. No login required. Nothing is uploaded or shared.